IOVA Share Price Performance
US$4.07
0.55 (15.63%)
51.3% undervalued intrinsic discount
US$8.35
Fair Value
Price US$4.07
AnalystConsensusTarget US$8.35
AnalystLowTarget US$2.00
AnalystHighTarget US$17.00
Fair ValueUS$8.35
Share Pricen/a
Iovance Biotherapeutics, Inc. Stock Price
- 3 Narratives written by author
- 3 Comments on narratives written by author
- 140 Fair Values set on narratives written by author
IOVA Community Narratives
AN
Fair Value US$8.35 51.3% undervalued intrinsic discount
IOVA: Advanced Melanoma Approval and Equity Raise Will Drive Upside Potential
2users have liked this narrative
2users have commented on this narrative
78users have followed this narrative
AN
Fair Value US$2 103.5% overvalued intrinsic discount
Rising Interest Rates And Dilution Will Stifle TIL Progress
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$17 76.1% undervalued intrinsic discount
Amtagvi And New TIL Will Meet Aging Global Demand
2users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Rising Interest Rates And Dilution Will Stifle TIL Progress
Key Takeaways Sustained high costs, complex distribution, and slow commercialization delay profitability and threaten market share amid rising competition from newer cancer therapies. Ongoing financial challenges, including exposure to interest rates and revenue pressure from drug pricing scrutiny, heighten risk of shareholder dilution and reduced margins.Read more
132
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$2
103.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
1.41%
Future PE
153.08x
Price in 2029
US$2.45
Amtagvi And New TIL Will Meet Aging Global Demand
Key Takeaways Faster-than-expected physician adoption, expanded patient access, and greater operating efficiency could drive revenue and profitability substantially beyond current expectations. Strong first-mover advantage, broad patent protection, and pipeline innovation position Iovance for sustained growth and long-term revenue diversification.Read more
151
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$17
76.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
13.96%
Future PE
75.1x
Price in 2029
US$20.88
IOVA: Advanced Melanoma Approval and Equity Raise Will Drive Upside Potential
Key Takeaways Expanded distribution and positive clinical data are set to boost adoption of Amtagvi and strengthen revenue growth in oncology markets. Operational streamlining, new pipeline advancements, and global expansion efforts are expected to improve profitability and diversify long-term earnings.Read more
1.7k
users have viewed this narrative2users have liked this narrative
2users have commented on this narrative
78users have followed this narrative
AN
US$8.35
51.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
3.6%
Future PE
183.52x
Price in 2029
US$10.27
Trending Discussion
Recently Updated Narratives
AN
IOVA: Elevated Future P/E Will Likely Clash With 2026 Clinical Data Risks
Fair Value: US$2 103.5% overvalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IOVA: Reaffirmed 2025 Revenue Outlook Will Support A Higher Future P/E
Fair Value: US$17 76.1% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IOVA: Lung Cancer Trial Progress Will Drive Bullish Repricing Ahead
Fair Value: US$8.35 51.3% undervalued intrinsic discount
78 followersusers have followed this narrative
2 commentsusers have commented on this narrative
1 likeusers have liked this narrative
Snowflake Analysis
Iovance Biotherapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.95
- 34.28%
- -148.38%
- 0.1%
About IOVA
- Founded
- 2007
- Employees
- 975
- CEO
- WebsiteView website
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
